Arylamine N-acetyltransferases (NATs) catalyze the biotransformation of a number of aromatic and heterocyclic amines, many of which are procarcinogenic agents. Interestingly, these enzymes are binary in nature, participating in both detoxification and activation reactions, and thus it is unclear what role NATs actually play in either preventing or enhancing toxic responses. The ultimate direction may be substrate-specific and dependent on its tissuespecific metabolism by competing, but genetically variable, drugmetabolizing enzymes. To investigate the effect of N-acetylation on the metabolism of some classical procarcinogenic arylamines, we have used our double knockout Nat1/2(؊/؊) mouse model to test both in vitro activity and the in vivo clearance of some of these agents. As expected, N-acetylation activity was undetectable in tissue cytosol preparations from Nat1/2(؊/؊) mice for 4-aminobiphenyl (ABP) and 2-aminofluorene (AF), whereas significant levels were measured in all wild-type tissue cytosols tested, indicating the widespread metabolism of these agents. Nat1/2(؊/؊) mice displayed a variable response with respect to in vivo pharmacokinetics. AF appeared to be most severely compromised, with a 3-to 4-fold increased area under the curve (AUC), whereas the clearance of ABP was found to be less dependent on N-acetylation, with no difference in ABP-AUC between wild-type and knockout animals. 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine was neither N-acetylated nor was its clearance affected by NAT genotype, signifying a dependence on other drug-metabolizing enzymes. The elucidation of the role that N-acetylation plays in the clearance of procarcinogenic agents is the first step in attempting to correlate metabolism by NATs to toxic outcome prevention or augmentation.
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Occupational or environmental exposure to arylamines has long been considered a causal factor for the development of human cancers (Weisburger, 2002) . A necessary prerequisite for these chemicals to exert their deleterious effects is biotransformation by various drugmetabolizing enzymes. In particular, the polymorphic arylamine Nacetyltransferases (NATs) catalyze the acetylation of these and other aromatic and heterocyclic amine drugs. Two isoenzymes, NAT1 and NAT2, are present in humans and exhibit unique tissue expression profiles and somewhat distinct but overlapping substrate specificities (for review, see Grant et al., 2000; Butcher et al., 2002) . Paradoxically, NATs can either facilitate the detoxification of carcinogenic arylamines into innocuous metabolites by N-acetylation or promote their metabolic activation into DNA-binding electrophiles via Oacetylation (Hein, 2002) . Such procarcinogenic arylamines include the bladder cancer agent 4-aminobiphenyl (ABP), which is found in tobacco smoke (Stabbert et al., 2003) and commercial hair dyes (Turesky et al., 2003) , and 2-aminofluorene (AF), an agent whose N-acetylated derivative was originally developed as an insecticide (Heflich and Neft, 1994) , but which is used now only as a model compound for studying mechanisms of metabolic activation in chemically induced mutagenesis and carcinogenesis. In addition, heterocyclic aromatic amines found in grilled meats, poultry, and fish, such as 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP), are considered as potential etiologic agents in human cancers (Weisburger, 2002) .
The following two-step activation model has been proposed for the conversion of procarcinogenic arylamines into DNA-binding molecules. The arylamine is first N-oxidized to an arylhydroxylamine by one or more isoforms of cytochrome P450, such as CYP1A2 present in the liver (see Kim and Guengerich, 2005) . Subsequent O-conjugation by NATs leads to the formation of highly unstable acetoxy esters that decompose into DNA-binding arylnitrenium ions (Hein, 2002) . Competing with the N-oxidation in the liver is N-acetylation by NATs, a step that converts potentially carcinogenic arylamines into N-acetate metabolites which are, in many cases, less carcinogenic than the parent compound. The balance of these pathways and their cellspecific expression profiles may thus determine the toxic endpoint in a particular tissue upon arylamine exposure.
Numerous studies have documented either the extent of DNA binding, mutational frequency and spectra, or the tumorigenic potential of ABP, AF, or PhIP in various animal models (Schieferstein et al., 1985; Flammang et al., 1992; Levy and Weber, 1992; Poirier et al., 1995; Fletcher et al., 1998) , human tissue samples (Airoldi et al., 2002; Faraglia et al., 2003) , cell cultures (Feng et al., 2002) , and NAT-expressing Salmonella typhimurium strains (Grant et al., 1992; Oda, 2004) . Results from these studies clearly indicate that these agents are mutagenic and/or require metabolic activation. Furthermore, epidemiological studies have alluded to a link between acetylation status and certain cancers, particularly of the colon and bladder (see Hein et al., 2000 , for review), but results have been inconsistent because of differences in sample size, genotyping/phenotyping discordances, and variable exposure situations.
Whereas epidemiological and in vitro studies have proposed a link between various drug-metabolizing enzymes as either risk modifiers or mediators of increased mutagenicity, results from whole animal studies involving knockout mouse models have revealed some unexpected results. In particular, Cyp1a2 knockout mice do not have lower ABP-DNA adducts (Tsuneoka et al., 2003) or attenuated ABP-induced methemoglobinemia (Shertzer et al., 2002) , nor do these animals display an increased protection against either ABP (Kimura et al., 1999 )-or PhIP-induced carcinogenesis (Kimura et al., 2003) . Furthermore, Cyp1a1 knockout mice exhibited a slower rate of clearance of benzo[a]pyrene upon oral exposure but a much greater toxicity (Uno et al., 2004) , despite in vitro studies that indicate a facilitatory role for CYP1A1 in benzo[a]pyrene toxicity (Schmalix et al., 1993) . These studies undoubtedly emphasize the importance of performing in vivo studies in conjunction with in vitro studies to be able to fully understand the potential interplay between multiple enzyme systems, their tissue-specific expression patterns, and the effect of clearance on activation.
Using a mouse model deficient in both NAT1 and NAT2, namely, our Nat1/2(Ϫ/Ϫ) model (Sugamori et al., 2003) , we have investigated the effect of acetylation on the metabolism and clearance of the procarcinogens ABP, AF, and PhIP. This is a necessary step in dissecting out the importance of acetylation on the metabolism and clearance of these compounds in the whole animal. Although NAT knockout models (Cornish et al., 2003; Sugamori et al., 2003) do not exhibit a deleterious phenotype, which would be indicative of a potential developmental role, these models are extremely useful in toxicity/carcinogenicity testing (Gonzalez, 2003) , and for delineating the relative contribution of various enzyme biotransformation reactions to detoxification and/or bioactivation in the whole animal.
Materials and Methods
Materials. F2 Nat1/2(ϩ/ϩ) and Nat1/2(Ϫ/Ϫ) mice on a mixed genetic B6/129 background were generated as described previously (Sugamori et al., 2003) . All procedures involving animals were used in accordance with the Canadian Council for Animal Care guidelines. Acetyl-DL-carnitine, carnitine acetyltransferase, acetyl-CoA sodium salt, ABP, AF, and AAF used for NAT activity assays were acquired from Sigma-Aldrich Canada Ltd. (Oakville, ON, Canada). AABP to use as a standard was produced in definable quantities from ABP using wild-type recombinant human NAT1 as a catalyst (Sugamori et al., 2003) . PhIP was purchased from Toronto Research Chemicals (Toronto, ON, Canada), and APhIP was generously provided by Dr. M. Novak (Miami University, Oxford, OH).
In Vitro NAT Enzyme Activity. Tissue cytosols were prepared from Nat1/2(ϩ/ϩ) and Nat1/2(Ϫ/Ϫ) animals as described (Sugamori et al., 2003) . NAT activity for ABP and AF N-acetylation was determined using various tissue cytosols (n ϭ 3 per gender, genotype, and tissue). Initial enzyme velocities for cytosolic fractions were performed in duplicate in final reaction volumes of 100 l, each consisting of 10 l of ABP or AF solution (giving a final concentration of 0.1 mM), 20 l of 0.5 mM acetyl-CoA (giving a final concentration of 0.1 mM), 20 l of an acetyl-CoA regenerating system composed of 5 mM acetyl-DL-carnitine and 1 U of carnitine acetyltransferase per milliliter of assay buffer (250 mM triethanolamine-HCl, 5 mM EDTA, 5 mM dithiothreitol, pH 7.5), and 50 l of diluted cytosol at a protein concentration of 1 g/l. Reactions were initiated with the addition of the cytosol to the remaining preheated components, incubated for 10 min at 37°C, and terminated by the addition of 10 l of 15% perchloric acid. For PhIP, the reactions were initiated with either 50 or 100 g of cytosolic protein and were allowed to proceed for 60 min at 37°C with up to 0.5 mM PhIP. After precipitation of the denatured protein, the supernatant fractions were assayed for the N-acetylated product (AABP, AAF, or APhIP) by HPLC using a Shimadzu LC-2010A system (Shimadzu Scientific Instruments Inc., Columbia, MD) and a reverse-phase Beckman Ultrasphere ODS 5-m column (15 cm ϫ 4.6 mm i.d.; Beckman Coulter, Fullerton, CA). A flow rate of 2 ml/min with a mobile phase consisting of 66% sodium perchlorate buffer (20 mM, pH 2.5)/34% acetonitrile and an ultraviolet detector setting of 280 nm were used for ABP and AF. For PhIP, the mobile phase consisted of 85% sodium perchlorate buffer/15% acetonitrile and the ultraviolet detector setting was 317 nm. Under these conditions, retention times of parent compound and acetylated metabolite were, respectively, 1.4 min and 3.7 min (AF and AAF), 1.4 min and 3.3 min (ABP and AABP), and 6.8 min and 6.2 min (PhIP and APhIP).
Drug Administration and Plasma Elimination Kinetics. ABP (50 mg/kg), AF (50 mg/kg), or PhIP (50 mg/kg) dissolved in dimethyl sulfoxide was administered by i.p. injection to 8-to 9-week-old ageand sex-matched Nat1/2(Ϫ/Ϫ) mice (n ϭ 4) and wild-type sibs (n ϭ 4). Blood samples were drawn from the saphenous vein using hepa- FIG. 1 . N-Acetylation rates in cytosols from wild-type and Nat1/2(Ϫ/Ϫ) mice. Tissue cytosols from wild-type and Nat1/2(Ϫ/Ϫ) mice were assayed for NAT activity with either 0.1 mM AF (A) or 0.1 mM ABP (B) in the presence of 0.1 mM acetyl-CoA as described under Materials and Methods. AAF and AABP were separated and quantified by HPLC. Product formation rates represent the mean from n ϭ 3 wild-type or knockout animals, respectively. Cortex ϭ cerebral cortex of the brain. Detection limits for N-acetylated product formation rates were 0.01, 0.02, and 0.02 nmol/min/mg for AAF, AABP, and APhIP, respectively.
SUGAMORI ET AL.
at ASPET Journals on January 20, 2018 dmd.aspetjournals.org rinized Microvettes (Sartstedt Inc., Montreal, QC, Canada) at four sequential time points and centrifuged to separate plasma. The time points for AF plasma sampling were 2, 6, 22, and 24 h for female knockout mice, and 1, 2, 4, and 6 h for female wild-type, male wild-type, and male knockout mice. ABP plasma sampling times were 2, 6, 22, and 24 h for both genders and all genotypes. PhIP plasma sampling times were 30 min, 60 min, 90 min, and 120 min for all animals. Plasma samples were diluted 1:50 in HPLC mobile phase, and analyzed for parent and acetylated metabolites by HPLC as described above. Blank plasma samples were spiked with known amounts of AF and AAF, ABP and AABP, or PhIP and APhIP to quantify the amount of parent and acetylated products present in the samples. Area under the curve (AUC) values were determined by the trapezoidal rule using the computer program Prism (GraphPad Software Inc., San Diego, CA). Statistical analyses were performed using a Student's t test with GraphPad Prism.
Results
ABP and AF in Vitro NAT Enzyme Activity. Nat1/2(Ϫ/Ϫ) mice displayed no measurable cytosolic ABP-or AF-NAT activity in any tissue assayed, whereas their wild-type controls displayed quantifiable NAT activity in all tissues (Fig. 1) . A gender difference in acetylation using kidney cytosol was noted in the B6/129 F2 wild-type mice. Male kidney cytosol displayed about a 2-fold higher activity ( p Ͻ 0.001) than female kidney cytosol for both AF and ABP. No other tissue cytosols displayed a gender difference in NAT activity in the wild-type animals. No PhIP N-acetylation could be detected in liver tissue cytosol from either wild-type or knockout animals (data not shown).
In Vivo NAT Activity and Plasma Pharmacokinetics. Consistent with the in vitro results, Nat1/2(Ϫ/Ϫ) mice exhibited no ability to N-acetylate either ABP or AF upon in vivo administration. Clearance for ABP appeared to be less dependent on the formation of its N-acetylated metabolite, as determined by the small AUC values for AABP compared with ABP in the wild-type animals (Fig. 2 , A and C) and the lack of a significant change in the ABP-AUC values in the knockout animals compared with wild-type (Table 1) . Knockout animals for both genders did display a complete absence of AABP (Fig.  2, B and D) . The lack of a significant difference between wild-type and knockout animals for ABP-AUC values indicates that N-acetylation does not appear to play a major role in the in vivo elimination of ABP. In addition, AABP was not detected in urine samples from wild-type animals (data not shown). In contrast, the absence of functional NAT1 and NAT2 appeared to impair the clearance of AF, with ϳ3-to 4-fold higher AF-AUC values from the knockout animals compared with wild-type for both genders (Figs. 3 and 4) , although the mean AF-AUC value for wild-type females was approximately 3-fold higher than that for wild-type males (Table 1 , p Ͻ 0.05). Knockout animals displayed a complete absence of N-acetylated metabolite in all plasma samples analyzed (Fig. 3, B and D). The small AUC values for AAF compared with AF may indicate that this metabolite is rapidly cleared from plasma.
N-acetylated PhIP could not be detected in the plasma samples from either the wild-type or knockout animals (Fig. 5) . AUC values for the parent PhIP were not significantly different between wild-type and knockout animals ( 
Discussion
The double Nat1/2 knockout model was used to investigate the effect of N-acetylation on the metabolism of the aromatic and heterocyclic amine procarcinogens, ABP, AF, and PhIP. In vitro enzyme assays using various tissue cytosols from the Nat1/2(Ϫ/Ϫ) revealed a complete absence of either N-acetylated ABP or AF. In contrast, the N-acetylated metabolites of ABP or AF were observed in all tissues assayed from wild-type animals, indicating the widespread functional expression of NAT. Most notably, NAT activity was observed in the bladder, a site susceptible to the formation of tumors upon ABP administration. No N-acetylation of PhIP could be detected even in our wild-type animals, indicating that PhIP is not a good substrate for N-acetylation by the mouse enzymes.
Consistent with our previous results using p-aminosalicylate as a substrate (Sugamori et al., 2003) and those using p-aminobenzoic acid and AF (Glowinski and Weber, 1982; Smolen et al., 1993 ), a gender difference was also observed in our wild-type mice with respect to kidney ABP-and AF-NAT activity. The activity in male kidney has been shown to be modulated by testosterone (Smolen et al., 1993) and is not unique to NATs inasmuch as CYP2E1 activity has also been shown to be higher in male kidney (Hoivik et al., 1995) . Whether this higher activity in kidney translates to any gender-related differences in arylamine adduct levels and a differential susceptibility to arylamine-induced carcinogenesis warrants further investigation. Indeed, gender differences have been observed with respect to the formation of ABP-and AF-DNA adducts in the bladder and the incidence of ABP-induced bladder cancers. In general, male mice were found to have higher DNA adducts in the bladder and a higher bladder tumor incidence (Schieferstein et al., 1985; Flammang et al., 1992; Levy and Weber, 1992; Poirier et al., 1995; Tsuneoka et al., 2003) . Female mice, on the other hand, had higher liver DNA adduct levels (Levy and Weber, 1989; Poirier et al., 1995; Tsuneoka et al., 2003; Chen et al., 2005) and a higher incidence of liver cancer (Schieferstein et al., 1985; Poirier et al., 1995) . . AUC values for AF and AAF were 28.5 and 2.0 mmol min/l. B, plasma kinetics of AF and AAF from a representative knockout male mouse. AUC for AF was 72.9 mmol min/l. C, plasma kinetics of AF and AAF from a representative wild-type female mouse. AUC values for AF and AAF were 54.7 and 5.5 mmol min/l, respectively. D, plasma kinetics of AF and AAF from a representative knockout female mouse. AUC value for AF was 251 mmol min/l. For all mice, AF (50 mg/kg) was administered by i.p. injection, and four sequential blood samples were drawn from the saphenous vein of each mouse at the indicated time points. Plasma was isolated from each blood sample, diluted 1:50 and analyzed for AF and AAF by HPLC. AUC values were determined by the trapezoidal rule using the computer program Prism (GraphPad Software Inc.). Detection limit for the N-acetylated metabolite was 4 M.
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To determine the effect of the absence of functional NAT1 and NAT2 activity on the clearance of ABP, AF, and PhIP, in vivo elimination studies were undertaken. The clearance of ABP from plasma was essentially unchanged in the Nat1/2(Ϫ/Ϫ) mice, thereby indicating that N-acetylation does not appear to be a major determinant of the clearance of ABP in the mouse. Contrary to ABP, the in vivo clearance of AF was found to be impaired in the Nat1/2(Ϫ/Ϫ) mice, as determined by the 3-to 4-fold increase in AF-AUC values for the knockout animals compared with wild-type. Although very low levels of AF N-acetylation have been observed with recombinant NAT3 (Kelly and Sim, 1994) , no detectable AAF was observed in our knockout animals using both in vitro activity assays and in vivo elimination studies. Clearance for AF appeared to be slower in female mice, regardless of genotype. It remains to be seen whether the previously observed gender-related differences in liver AF-DNA adducts, namely, that female mice have higher hepatic AF-DNA adducts, is related to this difference in clearance.
The clearance of PhIP was not dependent on N-acetylation. AUC values for PhIP were not significantly different between wild-type and knockout animals. Acetylated PhIP could not be detected in any of the plasma samples, confirming previous results in which PhIP was found to be a poor substrate for N-acetylation (Minchin et al., 1992) . However, the rather small AUC for the parent compound compared with AF and ABP suggests that PhIP is rapidly cleared from plasma. This would implicate the involvement either of other drug-metabolizing enzymes or enzymatic reactions in the clearance of PhIP from mice, redistribution into another poorly accessible tissue compartment, or efficient renal elimination. PhIP has been shown to be preferentially metabolized by 4Ј-hydroxylation in wild-type mice, a step that is considered to be a detoxification step with 4Ј-PhIP-sulfate, a main urinary product formed (Buonarati et al., 1992) , whereas in humanized CYP1A2 mice, N 2 -hydroxylation or activation was found to be the predominant pathway (Cheung et al., 2005) . This may account for the generally higher tumor incidence in Cyp1a2(Ϫ/Ϫ) mice exposed to PhIP (Kimura et al., 2003) , since 4Ј-hydroxylation or detoxification is a major pathway in wild-type mice, and thus, CYP1A2 may actually have a more protective role in wild-type mice.
The results using our double Nat1/2 knockout model indicate that the procarcinogens ABP, AF, and PhIP display a differential dependence on N-acetylation for clearance. What effect this may have with respect to the formation of DNA adducts and tumor incidence remains to be determined. Studies using congenic rapid and slow Nat2 acetylator mice and a transgenic mouse model expressing human NAT1 found no correlation between murine NAT2 activity or human NAT1 expression and ABP-DNA adduct levels in liver (McQueen et al., 2003) . It was proposed that the activation of ABP may be masked by competing reactions since ABP is a substrate for both NAT1 and NAT2 (Fretland et al., 1997) , and thus, a mouse model lacking both enzymes, such as our Nat1/2(Ϫ/Ϫ) mice, may be needed to assess the full impact of variation of acetylation capacity to the formation of ABP-DNA adducts. However, if clearance does affect the extent of APhIP from a representative knockout male mouse. AUC for PhIP was 4.9 mmol min/l. C, plasma kinetics of PhIP and APhIP from a representative wild-type female mouse. AUC value for PhIP was 6.3 mmol min/l, respectively. D, plasma kinetics of PhIP and APhIP from a representative knockout female mouse. AUC value for PhIP was 6.3 mmol min/l. For all mice, PhIP (50 mg/kg) was administered by i.p. injection, and four sequential blood samples were drawn from the saphenous vein of each mouse at the indicated time points. Plasma was isolated from each blood sample, diluted 1:50, and analyzed for PhIP and APhIP by HPLC. AUC values were determined by the trapezoidal rule using the computer program Prism (GraphPad Software Inc.). Detection limit for the N-acetylated metabolite was 10 M.
DNA adduct formation, then N-acetylation per se may not greatly influence ABP-DNA adduct formation. In contrast, AF-DNA adduct formation may be more greatly influenced by N-acetylation, since clearance in the Nat1/2(Ϫ/Ϫ) mice exhibited a greater dependence on acetylation. The prolonged retention of the chemical may allow for a potentially increased toxic response, as shown with the slower clearance of benzo[a]pyrene in Cyp1a1(Ϫ/Ϫ) mice upon its oral administration and the formation of higher DNA adducts (Uno et al., 2004) .
Nevertheless, the situation is not that simple; localized O-acetylation within tissues, such as the bladder, that are particularly susceptible to arylamine-induced carcinogenesis may play a more crucial role in shaping toxic outcomes upon arylamine exposure. Although PhIP does not appear to be N-acetylated, studies indicate that the N-OH-PhIP metabolite can be subjected to O-acetylation (Fretland et al., 2003) . In addition, other enzymes such as sulfotransferases can also participate in the bioactivation of some of these compounds (Fretland et al., 2003) , and thus, a multitude of enzyme systems can influence whether or not toxic endpoints occur. Indeed, sulfation has been suggested to be a primary route of bioactivation of the Nhydroxy metabolites of AF and AAF in the mouse (Lai et al., 1987; Miller, 1994) . Insofar as NATs can also contribute to either outcome, the clearance of procarcinogens by this pathway may influence the extent or balance of such other potential bioactivation reactions. Tissue DNA adduct studies after arylamine exposure in our knockout animal model and tumor bioassays will be of fundamental importance in addressing whether NATs play a more important role in facilitating or preventing toxic endpoints.
